| |
ABRP infections
|
Non-ARP infections
|
No infections
|
P-value
|
|---|
|
Population overall (N = 351)
|
N = 58
|
N = 57
|
N = 236
| |
|---|
|
Intra-ICU outcomes
|
|
Critical Illness Myopathy
|
22 (37.9)
|
11 (19.3)
|
9 (3.8)
|
< 0.001
|
|
Tracheostomy on discharge
|
19 (15.5)
|
11 (19.3)
|
8 (3.4)
|
< 0.001
|
|
Length of stay, days
|
29.6 ± 21.1
|
16.6 ± 13.6
|
6.6 ± 7.7
|
< 0.001a,b,c
|
|
MV days
|
23.3 ± 17.6
|
13.1 ± 10.8
|
4.6 ± 6.7
|
< 0.001a,b,c
|
|
ICU cost/patient, euros
|
13,515 ± 7761
|
8330 ± 5698
|
4183 ± 3877
|
< 0.001a,b,c
|
|
Intra-ICU mortality
|
24 (41.4)
|
18 (31.6)
|
56 (23.7)
|
0.022
|
|
Post-ICU outcomes
|
|
90-day mortality
|
42 (72.4)
|
33 (57.9)
|
109 (46.2)
|
0.001
|
|
2-year mortality
|
46 (79.3)
|
37 (64.9)
|
133 (56.36)
|
0.005
|
|
0.5-year QALYs
|
0.041 ± 0.085
|
0.073 ± 0.106
|
0.057 ± 0.097
|
0.077
|
|
1-year QALYs
|
0.105 ± 0.219
|
0.180 ± 0.265
|
0.142 ± 0.245
|
0.098
|
|
1.5-year QALYs
|
0.167 ± 0.358
|
0.289 ± 0.433
|
0.228 ± 0.4
|
0.101
|
|
2-year QALYs
|
0.228 ± 0.501
|
0.399 ± 0.604
|
0.313 ± 0.559
|
0.101
|
|
ICU survivors (N = 253)
|
N = 34
|
N = 39
|
N = 180
| |
|
90-day mortality
|
18 (52.9)
|
15 (38.5)
|
53 (29.4)
|
0.024
|
|
2-year mortality
|
22 (64.7)
|
19 (48.7)
|
103 (57.2)
|
0.061
|
|
0.5-year QALYs
|
0.070 ± 0.102
|
0.107 ± 0.113
|
0.159 ± 0.142
|
0.001b
|
|
1-year QALYs
|
0.179 ± 0.263
|
0.264 ± 0.285
|
0.380 ± 0.341
|
0.002 b
|
|
1.5-year QALYs
|
0.285 ± 0.432
|
0.423 ± 0.468
|
0.594 ± 0.543
|
0.003 b
|
|
2-year QALYs
|
0.389 ± 0.608
|
0.584 ± 0.654
|
0.808 ± 0.747
|
0.004 b
|
- Continuous data are presented as means ± SD, categorical data as n (%)
- ICU intensive care unit, ABRP antibiotic resistant pathogen, MV days days on mechanical ventilation, QALY quality-adjusted life years
- aP < 0.05, ABRP versus non-ABRP group
- bP < 0.05, ABRP versus no-infection group
- cP < 0.05, non-ABRP versus no-infection group (Bonferroni’s post hoc analysis)
